Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Comprehensive Dermatologic Drug Therapy

Comprehensive Dermatologic Drug Therapy

9780323612111
720.67 zł
612.57 zł Save 108.10 zł Tax included
Lowest price within 30 days before promotion: 612.57 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DHL, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

**Sel‎ected for Doody’s Core Titles® 2024 in Dermatology**

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you’re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on todays full spectrum of topical, intralesional, and systemic drugs. You’ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.

Product Details
Elsevier
81394
9780323612111
9780323612111

Data sheet

Publication date
2020
Issue number
4
Cover
hard cover
Pages count
858
Dimensions (mm)
216 x 276
Weight (g)
2540

  • Part I: Introduction
    1. Basic Principles of Pharmacology
    2. Principles for Maximizing the Safety of Dermatologic Drug Therapy
    3. Polymorphisms: Why Individual Drug Responses Vary
    4. Adherence to Drug Therapy
    5. Medical Decision Making

    Part II: Important Drug Regulatory Issues
    6. The FDA Drug Approval Process
    7. Pharmacovigilance: Verifying that Drugs Remain Safe
    8. Drugs Taken Off the Market: Important Lessons Learned

    Part III: Systemic Drugs for Infectious Diseases
    9. Systemic Antibacterial Agents
    10. Systemic Antifungal Agents
    11. Systemic Antiviral Agents
    12. Systemic Antiparasitic Agents

    Part IV: Systemic Immunomodulatory Drugs
    13. Systemic Corticosteroids
    14. Methotrexate
    15. Azathioprine
    16. Mycophenolates
    17. Cyclosporine
    18. Phosphodiesterase-4 and Janus Kinase Inhibitors
    19. Cytotoxic Agents
    20. Dapsone
    21. Antimalarial Agents
    22. Systemic Retinoids

    Part V: Drugs Used in Conjunction with UV or Visible Light
    23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities
    24. Extracorporeal Photochemotherapy (Photopheresis)
    25. Photodynamic Therapy

    Part VI: Biologic Therapeutics
    26. Tumor Necrosis Factor Inhibitors
    27. Interleukin 12/23 Inhibitors
    28. Interleukin 17 Inhibitors
    29. Interleukin 23 Inhibitors
    30. Rituximab
    31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

    Part VII: Miscellaneous Systemic Drugs
    32. Antihistamines
    33. Vasoactive and Antiplatelet Agents
    34. Antiandrogens and Androgen Inhibitors
    35. Psychotropic Agents
    36. Intravenous Immunoglobulin Therapy
    37. Systemic Anticancer Agents: Dermatologic Indications and Adverse Events
    38. Hedgehog Pathway Inhibitors
    39. Drugs for the Skinternist
    40. Miscellaneous Systemic Drugs

    Part VIII: Topical Drugs for Infectious Diseases
    41. Topical Antibacterial Agents
    42. Topical Antifungal Agents
    43. Topical and Intralesional Antiviral Agents
    44. Topical Antiparasitic Agents

    Part IX: Topical Immunomodulatory Drugs
    45. Topical Corticosteroids
    46. Topical Retinoids
    47. Topical and Intralesional Chemotherapeutic Agents
    48. Topical Calcineurin Inhibitors
    49. Topical Vitamin D3

    Part X: Miscellaneous Topical Drugs
    50. Sunscreens
    51. Therapeutic Shampoos
    52. ?-Hydroxy Acids
    53. Chemical Peels
    54. Products for the Care of Chronic Wounds
    55. Agents Used for Treatment of Hyperkeratosis
    56. Irritants and Allergens: When to Suspect Topical Therapeutic Agents
    57. Miscellaneous Topical Agents

    Part XI: Injectable and Mucosal Routes of Drug Administration
    58. Local Anesthetics
    59. Injectable Dermal and Subcutaneous Fillers
    60. Botulinum Toxin Injections
    61. Oral Mucosal Therapeutics

    Part XII: Major Adverse Effects From Systemic Drugs
    62. Hepatotoxicity of Dermatologic Drug Therapy
    63. Hematologic Toxicity of Drug Therapy
    64. Drug-induced Malignancy
    65. Dermatologic Drugs During Pregnancy and Lactation
    66. Drug Interactions
    67. Cutaneous Drug Reactions With Systemic Features

    Part XIII: Special Pharmacology and Therapeutics Topics
    68. Informed Consent and Risk Management
    69. Compounding in Dermatology
    70. Dermatologic Drug Therapy in Children

    Appendix
    I Core Questions for Understanding Systemic Dermatologic Drugs
    II The Most Potentially Serious Drug Interactions

Comments (0)